Horizon Pharma (NASDAQ:HZNP) was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued to investors on Wednesday.

Other equities analysts also recently issued research reports about the stock. Mizuho reissued a “buy” rating and set a $18.00 target price on shares of Horizon Pharma in a research note on Monday, May 7th. Cantor Fitzgerald set a $17.00 target price on shares of Horizon Pharma and gave the stock a “buy” rating in a research note on Sunday, April 15th. Piper Jaffray reissued a “buy” rating and set a $22.00 target price on shares of Horizon Pharma in a research note on Thursday, March 1st. Cowen reissued a “buy” rating and set a $24.00 target price on shares of Horizon Pharma in a research note on Thursday, March 1st. Finally, UBS set a $20.00 target price on shares of Horizon Pharma and gave the stock a “buy” rating in a research note on Thursday, March 1st. Four equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $19.20.

Shares of NASDAQ HZNP opened at $15.07 on Wednesday. Horizon Pharma has a twelve month low of $14.83 and a twelve month high of $15.01. The firm has a market cap of $2.46 billion, a P/E ratio of 12.77, a PEG ratio of 0.88 and a beta of 1.29. The company has a quick ratio of 1.50, a current ratio of 1.56 and a debt-to-equity ratio of 2.17.

Horizon Pharma (NASDAQ:HZNP) last announced its earnings results on Wednesday, May 9th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.08). Horizon Pharma had a positive return on equity of 16.97% and a negative net margin of 45.06%. The firm had revenue of $223.88 million for the quarter, compared to the consensus estimate of $232.05 million. During the same period in the prior year, the business earned $0.21 EPS. Horizon Pharma’s quarterly revenue was up 1.4% on a year-over-year basis. research analysts predict that Horizon Pharma will post 1.43 EPS for the current fiscal year.

A number of large investors have recently bought and sold shares of the business. William Blair Investment Management LLC grew its holdings in Horizon Pharma by 12.2% in the fourth quarter. William Blair Investment Management LLC now owns 8,826,079 shares of the biopharmaceutical company’s stock worth $128,861,000 after purchasing an additional 958,414 shares during the period. venBio Select Advisor LLC grew its holdings in Horizon Pharma by 16.3% in the first quarter. venBio Select Advisor LLC now owns 5,158,683 shares of the biopharmaceutical company’s stock worth $73,253,000 after purchasing an additional 722,500 shares during the period. Brandywine Global Investment Management LLC grew its holdings in Horizon Pharma by 3.7% in the fourth quarter. Brandywine Global Investment Management LLC now owns 4,160,474 shares of the biopharmaceutical company’s stock worth $60,743,000 after purchasing an additional 149,854 shares during the period. Renaissance Technologies LLC grew its holdings in Horizon Pharma by 105.5% in the fourth quarter. Renaissance Technologies LLC now owns 2,279,400 shares of the biopharmaceutical company’s stock worth $33,279,000 after purchasing an additional 1,170,000 shares during the period. Finally, Northern Trust Corp grew its holdings in Horizon Pharma by 0.5% in the first quarter. Northern Trust Corp now owns 1,967,642 shares of the biopharmaceutical company’s stock worth $27,940,000 after purchasing an additional 9,366 shares during the period. Institutional investors and hedge funds own 87.24% of the company’s stock.

About Horizon Pharma

Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients.

Analyst Recommendations for Horizon Pharma (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.